SUMMARY The effects of 1 and 4 ,ug/kg/h somatostatin on pentagastrin-stimulated gastric mucosal blood flow and acid secretion were investigated in 12 normal subjects and in 12 patients with cirrhosis of the liver. Each dose of somatostatin was given intravenously to six normal subjects and to six patients. Gastric mucosal blood flow was measured by the neutral red clearance of the stomach. Pentagastrin at a dose of 0 67 ,ug/kg/h stimulated acid secretion less in patients with cirrhosis of the liver than in normal subjects. In normal subjects 1 ,ug/kg/h somatostatin induced a parallel decline of gastric mucosal blood flow and gastric secretion; with 4 ,ug/kg/h somatostatin mucosal blood flow was inhibited more than gastric secretion. In patients with cirrhosis of the liver gastric mucosal blood flow remained unaffected by both doses of somatostatin, while acid secretion was slightly decreased. It is concluded that somatostatin can affect gastric mucosal blood flow independently of acid secretion. Somatostatin may be ineffective in the treatment of gastric haemorrhage in patients with cirrhosis of the liver.
In a controlled clinical trial somatostatin at a dose of 250 ,u g/kg/h has been shown to stop the acute haemorrhage from peptic lesions.' In normal subjects 250 ag/h somatostatin lowered splanchnic blood flow; in patients with cirrhosis of the liver wedged hepatic venous pressure and splanchnic blood flow remained unaffected by the same dose of somatostatin.2 Nevertheless, somatostatin has been claimed to be effective in the treatment of bleeding oesophageal varices.3 In order to elucidate further the effects of somatostatin on the blood supply to the mucosa in the gastrointestinal tract, mucosal blood flow during somatostatin infusion was measured by the neutral red clearance of the stomach in 12 normal subjects and in 12 patients with cirrhosis of the liver.
Methods

SUBJECTS
Twelve patients with cirrhosis of the liver (two women and 10 men) participated in the study; mean age was 52±15 years (x±SD). All patients had a history of excessive alcohol consumption.
Rece ic(d for publication 17 Neutral red was extracted from 10 ml of alkalinised blood samples and 3 ml of alkalinised gastric juice with diethylether according to the method of Knight et al. 5 6 and transferred to an acidic aqueous phase. The concentration of neutral red was measured by photometry at a wavelength of 540 nm. Acid output was determined by titration of 0.5 ml gastric contents with 0-1 n NaOH to a pH of 7.0 on an automatic titrator. Polyethylene glycol concentration was determined by the turbidimetric method of Malawer et al. (2) between the pentagastrin and the pentagastrin + somatostatin infusion were evaluated by the unpaired and paired Student's t-test, respectively.
Results
Neutral red appeared in the gastric juice three to six minutes after the bolus injection. After a brief rise, the concentration of neutral red in the gastric aspirates steadily declined during the first 30-45 minutes, while it remained virtually constant in the blood from the beginning onwards. Accordingly, the R-value and the neutral red clearance showed an initial fall before a steady state under pentagastrin was reached (Fig. 1) . The initial fall of the R-value and the neutral red clearance was more pronounced in the control group than in the patients with cirrhosis of the liver (Fig. 2) . Pentagastrin infusion induced an initial rise of acid secretion in the first hour; in the second hour acid secretion remained constant or showed a slight decrease. The 12 patients with cirrhosis had lower acid secretion, neutral red clearance, and R-values than the 12 controls (Table) .
In the control group somatostatin at a dose of 1 ,ug/kg/h induced a sharp fall of the pentagastrin stimulated acid secretion. As the neutral red clearance fell parallel to the volume and acid secretion, the R-value remained practically unchanged. (Fig. 1 ).
In the patients with liver cirrhosis 1 gg/kg/h somatostatin inhibited pentagastrin-stimulated acid secretion less than in the control group (Table) . In contrast with controls, neutral red clearance remained unaffected. The R-value slightly The neutral red clearance again remained unaffected, and the R-value significantly increased (Fig. 2) .
A significant linear correlation existed between gastric acid secretion and neutral red clearance. The positive intercepts of the regression lines with the y-axis representing neutral red clearance were similar in both groups of subjects (Fig. 3) .
In the control group and in the patients' group both concentrations of somatostatin left systolic and diastolic blood pressure and pulse rate unchanged compared with the pentagastrin period.
Discussion
In normal subjects low dose somatostatin induced a parallel decline of gastric secretion and mucosal blood flow; at a high dose, blood flow was inhibited more than gastric secretion. In patients with cirrhosis of the liver gastric mucosal blood flow remained unaffected by both doses of somatostatin.
For the measurement of gastric mucosal blood flow the neutral red clearance of the stomach was used. After the bolus injection neutral red accumulates inside the parietal cells and is consecutively washed out of the cells by the acid secretion." 12 The initial fall of the neutral red clearance and the R-value thus does not correspond with real changes of blood flow. Only the values of the second hour represent steady state of mucosal blood flow under pentagastrin. Gastric neutral red and aminopyrine clearance appear to reflect both Fig. 3 Linear regression between acid secretion and neutral red clearance during infusion ofpentagastrin given alone (left) or together with somatostatin (right). * Healthy subjects, E patients with cirrhosis ofthe liver, 0 healthy subject disregarded in the linear regression. For all r, p<OO5. gastric mucosal blood flow and parietal cell function. They should only be used as relative measures of gastric mucosal blood flow. These drawbacks of clearance markers in general must be considered when the results of the present study are to be interpreted. 12 Cirrhotic patients are less responsive to pentagastrin stimulated acid secretion than normal subjects. Because of the decreased capacity for acid secretion in these patients less neutral red is trapped in their mucosa after the bolus injection (Fig. 2) . It could mean that their parietal cells do respond less to stimulation, or it may reflect a restraint in blood flow. Unlike the healthy subjects, the cirrhotic patients exhibit a marked decrease of acid output only with a high dose of somatostatin, the decrease still being far less than in the healthy subjects. The reason for this diminished response is unknown. It has been shown that somatostatin is degraded by the liver.'3 Degradation may be impaired, thus leading to abnormally high levels of somatostatin in cirrhotic patients. With high pre-existing plasma levels of somatostatin, low dose infusion of somatostatin might be ineffective. This, however, is speculative, since no data on the pharmacokinetics of somatostatin in liver cirrhosis exist.
After After an intravenous infusion of 7-5 ,ug/min somatostatin to patients with cirrhosis of the liver, Bosch and coworkers have observed a 17.5% reduction in splanchnic blood flow measured by the indocyanine green method. 16 Little indocyanine green is extracted from the blood by the cirrhotic liver, however, and this change in blood flow may be below the range which can be detected by this method.'7 Sonnenberg et al using a smaller dose of 250 ,ug/h somatostatin have found a 33% decline of splanchnic blood flow in normal subjects, but no effect of somatostatin in patients with cirrhosis of the liver.2 These findings are corroborated by our results.
Total stimulated blood flow is a combination of resting flow (NRCT) and stimulated flow (NRCJ):
The greater the stimulated flow the less the contribution of resting flow to total flow, and, conversely; the less the stimulation the greater the contribution of resting to total flow. R then reflects the changing contributions of these two factors to total flow. In the absence of volume secretion there is still resting blood flow. The regression of blood flow vs volume or acid secretion has a positive intercept corresponding with NRC, (Fig. 3) . In the absence of acid secretion there is still trapping of neutral red by the induced acid environment after the infusion of extrinsic acid. It could, therefore, be concluded that, providing neutral red clearance reflects changes in blood flow, then the unchanged R-value after the infusion of I ,ug/kg/h somatostatin to healthy subjects is compatible with the blood flow restraining acid secretion. Somatostatin at a dose of 2-5 ,ug/kg/h caused a marked decrease of canine mucosal blood flow measured by the '4C-aminopyrine clearance.À s at this dose the R-value remained constant, the authors concluded that the reduction in mucosal blood flow was secondary to an inhibition of gastric secretion -a conclusion different from ours.
Our experiments with 4 ,g/kg/h somatostatin showed a decrease of the R-value in healthy subjects and an increase in liver cirrhosis, though in both groups somatostatin reduced gastric secretion. Thus, somatostatin, at least at high doses, can act independently, on both, gastric secretion and mucosal blood flow. The decrease of the R-value in healthy subjects suggests that somatostatin inhibits gastric mucosal blood flow more than gastric secretion. In cirrhotic patients the R-value increases during the somatostatin inhibition of the gastric mucosa because of a relative sparing of the mucosal blood flow. The splanchnic system seems to be particularly sensitive to somatostatin, while other vessel systems do not respond to it. 19 2) The sensitivity of the splanchnic system is disturbed by liver cirrhosis for unknown reasons. This has so far been demonstrated for the total splanchnic system and in this study for the gastric mucosal blood flow. Somatostatin may be ineffective in the treatment of gastric haemorrhage in patients with cirrhosis of the liver.
